Within the subgroup of studies with histological confirmation of the disease, FGF-21 levels were higher in patients with NASH than controls, but not in patients with NAFL compared to controls or patients with NASH [Table 3; Fig. S2a, S2c, S2e]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.